Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Decline in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 1,230,000 shares, a decline of 6.1% from the November 15th total of 1,310,000 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average daily volume of 712,600 shares, the short-interest ratio is presently 1.7 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

HOWL stock opened at $1.76 on Tuesday. Werewolf Therapeutics has a 12 month low of $1.58 and a 12 month high of $8.19. The firm has a market cap of $78.43 million, a P/E ratio of -1.08 and a beta of 0.30. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The company’s 50-day moving average price is $2.14 and its two-hundred day moving average price is $2.34.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its holdings in Werewolf Therapeutics by 130.1% during the 3rd quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after acquiring an additional 30,990 shares during the period. Geode Capital Management LLC raised its stake in Werewolf Therapeutics by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after buying an additional 40,692 shares during the period. XTX Topco Ltd bought a new position in Werewolf Therapeutics in the third quarter worth approximately $45,000. State Street Corp increased its holdings in shares of Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after acquiring an additional 52,528 shares in the last quarter. Finally, PFM Health Sciences LP raised its stake in Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after acquiring an additional 157,673 shares during the period. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.